Epigenomics' Epi proColon Blood Test Finally Makes The Grade With FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA approved the first blood-based colorectal cancer screening test, developed by Epigenomics, after a challenging regulatory path for the product, including a 2014 not-approvable letter.
You may also be interested in...
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test
CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.